These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23909263)

  • 1. [Effect of liver cirrhosis on pharmacokinetics and pharmacodynamics of drugs].
    Perlík F
    Vnitr Lek; 2013 Jul; 59(7):584-6. PubMed ID: 23909263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatic first-pass metabolism of problematic drugs.
    Lalka D; Griffith RK; Cronenberger CL
    J Clin Pharmacol; 1993 Jul; 33(7):657-69. PubMed ID: 8366191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver fibrosis impairs hepatic pharmacokinetics of liver transplant drugs in the rat model.
    Zou YH; Liu X; Khlentzos AM; Asadian P; Li P; Thorling CA; Robertson TA; Fletcher LM; Crawford DH; Roberts MS
    Drug Metab Pharmacokinet; 2010; 25(5):442-9. PubMed ID: 20877138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verapamil pharmacokinetics and liver function in patients with cirrhosis.
    Finucci GF; Padrini R; Piovan D; Melica E; Merkel C; Gatta A; Zuin R
    Int J Clin Pharmacol Res; 1988; 8(2):123-6. PubMed ID: 3378854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of the evaluation of blood supply and mass of the liver for predicting the rate of pharmacokinetics of lidocaine, propranolol and phenazone].
    Hartleb M; Kloc T; Mańczyk I; Becker A; Bołdys H
    Pol Arch Med Wewn; 1989 Jun; 81(6):321-9. PubMed ID: 2634249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmics: elimination and dosage considerations in hepatic impairment.
    Klotz U
    Clin Pharmacokinet; 2007; 46(12):985-96. PubMed ID: 18027986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
    Li P; Robertson TA; Thorling CA; Zhang Q; Fletcher LM; Crawford DH; Roberts MS
    Drug Metab Dispos; 2011 Apr; 39(4):571-9. PubMed ID: 21245286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hepatic insufficiency on pharmacokinetics and drug dosing.
    Verbeeck RK; Horsmans Y
    Pharm World Sci; 1998 Oct; 20(5):183-92. PubMed ID: 9820880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics in patients with liver disease.
    McLean AJ; Morgan DJ
    Clin Pharmacokinet; 1991 Jul; 21(1):42-69. PubMed ID: 1914341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug interactions with theophylline.
    Jonkman JH; Upton RA
    Clin Pharmacokinet; 1984; 9(4):309-34. PubMed ID: 6147220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
    Li P; Robertson TA; Zhang Q; Fletcher LM; Crawford DH; Weiss M; Roberts MS
    Pharm Res; 2012 Jun; 29(6):1658-69. PubMed ID: 22302523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal absorption and hepatic extraction of propranolol and metoprolol in rats with bilateral ureteral ligation.
    Okabe H; Higashi T; Ohta T; Hashimoto Y
    Biol Pharm Bull; 2004 Sep; 27(9):1422-7. PubMed ID: 15340230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearance by the liver in cirrhosis. III. Propranolol uptake by the isolated perfused human liver.
    Villeneuve JP; Dagenais M; Huet PM; Lapointe R; Roy A; Marleau D
    Can J Physiol Pharmacol; 1996 Dec; 74(12):1327-32. PubMed ID: 9047043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
    Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
    Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
    De Paepe P; Belpaire FM; Buylaert WA
    Clin Pharmacokinet; 2002; 41(14):1135-51. PubMed ID: 12405864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects.
    Murthy SS; Nelson WL; Shen DD; Power JM; Cahill CM; McLean AJ
    Drug Metab Dispos; 1991; 19(6):1093-100. PubMed ID: 1687016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
    Edginton AN; Willmann S
    Clin Pharmacokinet; 2008; 47(11):743-52. PubMed ID: 18840029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The inhibition of lidocaine metabolism by various barbiturates in rat hepatic microsome].
    Kakinohana M; Taira Y; Kakinohana O; Okuda Y
    Masui; 1998 Nov; 47(11):1302-10. PubMed ID: 9852692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic and pharmacodynamic characteristics of antihypertensive drugs in the treatment of hypertensive patients with chronic diseases of the liver].
    Mikheeva OM; Drozdov VN; Komisarenko IA
    Ter Arkh; 2011; 83(12):49-55. PubMed ID: 22416445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.